DUBLIN, Dec. 15, 2021 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a global Phase 2b clinical trial evaluating the safety and efficacy of suvecaltamide (also known as JZP385), a highly selective modulator of T-type calcium channels in development for the potential treatment of moderate to severe essential tremor (ET).1 The multicenter, double-blind, […]
TORONTO, Oct. 4, 2021 /CNW/ – A second-generation, streamlined and battery-free stabilizing glove that can adapt to a wider range of hand tremors in people with Essential Tremor and Parkinson’s disease has been developed by Canadian company Steadiwear Inc.
September 2021 – Recent gifts from generous donors have provided the International Essential Tremor Foundation with the opportunity to revamp its 20-year-old research grant program for a more meaningful and long-term impact. When the grant program was established in 2001, it entailed awarded up to two $25,000 grants per year to studies addressing the nosology, […]
BURLINGAME, Calif.–(BUSINESS WIRE)–Cala Health, a bioelectronic medicine company developing wearable therapies for chronic disease, announces two validating pieces of news for the non-invasive prescription therapy for essential tremor (ET), Cala Trio™. Real-world evidence of a Veteran Affairs (VA) patient population presented at The International Parkinson and Movement Disorder Society (MDS) 2021 virtual congress on September 15 showcases Cala […]
CAMBRIDGE, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.
CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today provided a corporate update and reported financial results for the first quarter ended March 31, 2021.
age Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of people with essential tremor (ET).
(Nature Neuroscience, March 18, 2021) Cannabinoids reduce tremor associated with motor disorders induced by injuries and neurodegenerative disease. Here we show that this effect is mediated by cannabinoid receptors on astrocytes in the ventral horn of the spinal cord, where alternating limb movements are initiated. We first demonstrate that tremor is reduced in a mouse […]
ABBOTT PARK, Ill., March 8, 2021 /PRNewswire/ — Abbott (NYSE: ABT) today announced the U.S. launch of NeuroSphere™ Virtual Clinic, a first-of-its-kind technology that allows patients to communicate with physicians, ensure proper settings and functionality, and receive new treatment settings remotely as needed. Approved by the U.S. Food and Drug Administration, the NeuroSphere Virtual Clinic has the […]
December 24, 2020 — Among patients with Parkinson disease (PD), a positive history of essential tremor (ET) was found to be associated with slower progression of motor and nonmotor symptoms, with no impact observed on survival, according to study findings published in Scientific Reports.